To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.

 
 

Description

N-acetylcysteine (NAC) has been widely used in the treatment of liver failure secondary to acetaminophen overdose. At Valley Hospital Medical Center (VHMC) and other Valley Health System hospitals, NAC has been used as an off-label treatment for non-acetaminophen-induced acute liver failure (NAI-ALF) and ischemic hepatitis. Studies have shown NAC is safe for use in NAI-ALF and may provide a survival benefit in native liver without transplantation. While some evidence suggests potential benefits of NAC for NAI-ALF, lack of robust, high-quality studies limits its widespread adoption and routine use. The objective of this study is to evaluate the effectiveness of NAC in reducing ALT and AST within 72 hours in patients with NAI-ALF.

Disciplines

Health Services Research | Medical Education | Medical Sciences | Medicine and Health Sciences

Keywords

N-acetylcysteine, non-acetaminophen-induced acute liver failure, NAC, NAI-ALF

Document Type

Poster

Share

COinS
 

Impact of N-acetylcysteine in non-acetaminophen-induced acute liver failure: A retrospective analysis

N-acetylcysteine (NAC) has been widely used in the treatment of liver failure secondary to acetaminophen overdose. At Valley Hospital Medical Center (VHMC) and other Valley Health System hospitals, NAC has been used as an off-label treatment for non-acetaminophen-induced acute liver failure (NAI-ALF) and ischemic hepatitis. Studies have shown NAC is safe for use in NAI-ALF and may provide a survival benefit in native liver without transplantation. While some evidence suggests potential benefits of NAC for NAI-ALF, lack of robust, high-quality studies limits its widespread adoption and routine use. The objective of this study is to evaluate the effectiveness of NAC in reducing ALT and AST within 72 hours in patients with NAI-ALF.